Retatrutide Titration Schedule: Complete 6-Month Escalation Guide for UAE Researchers (2026)
TL;DR. The Jastreboff 2023 NEJM protocol escalates retatrutide every 4 weeks from 0.5 mg to a maintenance dose of 4, 8, or 12 mg weekly SC. Each step requires confirmation that the previous dose was tolerated. The single biggest research mistake is escalating through unresolved nausea — it compounds and forces discontinuation.
The Foundation Protocol — Jastreboff 2023
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Phase 2 (Jastreboff 2023, NEJM) tested four dose targets: 1, 4, 8, and 12 mg weekly. Each arm titrated from a starting dose with 4-week increments. Weight loss at 48 weeks scaled with the dose: 8.7% at 1 mg, 17.5% at 4 mg, 22.8% at 8 mg, 24.2% at 12 mg.
REVIVE LAB UAE does not publish dosing, titration or administration schedules. The published trial literature cited on this page is the appropriate reference for study design.
The Three Dose Arms in Jastreboff 2023
4 mg weekly — Conservative
- ~17.5% weight loss at 48 weeks (Jastreboff 2023)
- Lower side-effect burden
- Slower descent, more sustainable for long-term research
- Commonly used for: longer time horizon, tolerability priority
8 mg weekly — Standard
- ~22.8% weight loss at 48 weeks
- Moderate side-effect burden, manageable
- Commonly used for: standard research protocols, balanced approach
12 mg weekly — Maximum
- ~24.2% weight loss at 48 weeks (curve still descending)
- Highest side-effect burden including 6–8 bpm HR elevation
- Commonly used for: maximal effect research, shorter time horizon
Vial Math For Each Step
REVIVE supplies retatrutide as 5 mg and 10 mg vials. Reconstitution math depends on your dose and BAC water volume — see our . Quick reference using a 10 mg vial + 2 mL BAC water (5 mg/mL):
| Dose | Draw volume (1mL syringe) | IU equivalent |
|---|---|---|
| 0.5 mg | 0.10 mL | 10 IU |
| 1 mg | 0.20 mL | 20 IU |
| 2 mg | 0.40 mL | 40 IU |
| 4 mg | 0.80 mL | 80 IU |
| 8 mg | 1.60 mL (two injections of 0.80 mL) | 2 x 80 IU |
| 12 mg | Use a 2 mL/200 IU syringe or split across days | 240 IU |
For doses above 4 mg, consider reconstituting with less BAC water for a more concentrated solution — e.g., 10 mg + 1 mL BAC water = 10 mg/mL, halving draw volume.
When to Slow or Hold the Schedule
- Persistent nausea beyond 2 weeks at current dose. Hold; do not escalate.
- Vomiting more than once per week. Reduce by one step.
- Resting heart rate jumps over 15 bpm above baseline. Hold; consult monitoring data.
- Severe abdominal pain. Stop immediately. Rule out pancreatitis with medical supervision.
- Gallbladder symptoms (RUQ pain after fatty meals). Hold; investigate.
Tolerability Tips That Actually Work
- Inject same day each week. Consistency reduces side-effect variability.
- Inject in evening — sleep through peak nausea window.
- Reduce dietary fat for first 48 hours post-injection. Slows gastric emptying, but a low-fat meal limits the worst of it.
- Increase fluid + electrolytes. Slowed GI motility loses water; constipation is a major secondary effect.
- Ginger and small frequent meals. Same logic that works for chemotherapy nausea applies here.
Deeper dive: .
UAE-Specific Considerations
- Refrigerate reconstituted vials immediately. UAE summer heat exposure shortens the 28-day shelf life — see storage guide.
- Plan around Ramadan if relevant. Fasting research subjects need timing adjustments to avoid hypoglycaemia overlap.
- Heat acclimation matters. GLP-1s can blunt thirst signalling; outdoor heat exposure during UAE summers increases dehydration risk.
Starting a retatrutide research protocol in the UAE?
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates, cold-chain delivery, and reconstitution support.
View retatrutide vials →
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates, cold-chain delivery, and reconstitution support.
View retatrutide vials →
Order Retatrutide in the UAE
HPLC-verified vials · Same-day Dubai dispatch · Cash on delivery · 24h nationwide.
Buy Retatrutide ›
Retatrutide UAE Page
Research use only. Retatrutide supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption. This page is informational and is not a recommendation. Any question that touches human health belongs with a qualified physician — nothing here replaces individual medical supervision.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234–1247.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–319.